The biotherapeutics pipeline is evolving and so are the tools to purify and manufacture therapeutic molecules. In the growing market of adeno-associated virus (AAV) vectors, the separation of AAV with high yield and purity is an increasingly important challenge. How can you leverage new tools to streamline your AAV process development?
Learn from MeiraGTx, a clinical-stage genetic medicine company, how in silico process development tools such as mechanistic modeling help you to optimize your gene therapy process.
All models are wrong, but some are useful: accelerating platform process development using mechanistic tools for an AAV product
Date: 21 November 2024
Time: Choose from 09:00–10:00 CET or 17:00–18:00 CET
Presenter: Alex Olivares-Molina, PhD; MSAT Senior Scientist I – Downstream Process Development at MeiraGT
